On March 31st, Thermo Fisher Scientific completed their acquisition of Affymetrix Inc. This happens as a possible bidding war was circling the horses around the deal between Thermo Fisher and Origin Technologies.
Affymetrix chose Thermo Fisher’s $1.3 billion bid over Origin’s $1.5 billion.
With this acquisition, Thermo Fisher will extend its antibody portfolio will which expand its market share in biosciences and its genetic analysis capabilities.
Thermo Fischer Scientific, $TMO, is currently down nearly 2% on today’s trading session.
